NMAP blood test to help distinguish renal cell cancer from non-renal cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study compares serum NMAP, a protein linked to nicotinamide metabolism, between adults with newly diagnosed renal cell carcinoma and non-renal cancer controls. The team will measure NMAP levels, construct a ROC curve, and determine cut-off values to differentiate the groups. Blood samples are collected as part of standard diagnostic pathways, and no therapeutic interventions are tested. The study is conducted at Xinhua Hospital in Shanghai and does not involve experimental treatments for cancer patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. The tumor group patients were found to have renal or hepatic mass, plan to receive surgical treatment (except for radiofrequency ablation, cryoablation, etc., which were not available for pathological examination). The control group patients were ruled out of tumor based on radiological tests and commonly used tumor biomarkers
2. Age ≥ 18 years old and able to provide written informed consent;
3. Have not received any systemic or topical treatment for kidney/liver tumors.
4. Cardiopulmonary, liver and kidney functions are able to tolerate surgery and can comply with research requirements.

Exclusion Criteria:

1. The investigators believe that the subject may be unsuitable for inclusion due to severe concurrent diseases, infections, and etc.
2. The subjects is known or suspected of other malignancies.
3. There has been another history of malignancy in the past 5 years.
4. Major surgery (surgery requiring general anesthesia) was performed within 4 weeks prior to screening visits.

Where it's running

• Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Min NA Shi, MD
• Email: shimin@xinhuamed.com.cn
• Phone: 021-25076143

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Belzutifan plus zanzalintinib versus belzutifan alone for advanced renal cell carcinoma

  This trial tests whether adding the targeted drug zanzalintinib to belzutifan helps people with advanced renal cell carcinoma live longer and delay tumor growth compared with belzutifan plus placebo.

  Recruiting at 107 sites Phase 3 Merck Sharp & Dohme LLC · Duarte, California and 110 other locations · NCT07489495

• PF-08634404 alone and with other anticancer medicines for adults with advanced kidney cancer.

  This tests whether PF-08634404, given alone or with other cancer medicines, is safe and helps adults with locally advanced or metastatic kidney cancer who have not had prior systemic treatment.

  Recruiting at 157 sites Phase 1/2 Pfizer · Phoenix, Arizona and 182 other locations · NCT07227415

• Deep-learning tool to distinguish T1–T2 from T3 renal cell carcinoma on contrast-enhanced CT.

  This project will see if a computer model can tell whether kidney cancer is early (T1–T2) or locally advanced (T3) using contrast-enhanced CT scans before surgery.

  Recruiting Peking University First Hospital · Beijing · NCT07166445

• Using vorolanib for treating advanced kidney cancer

  This study is testing if the drug vorolanib can help people with advanced kidney cancer live longer when used as a second treatment option.

  Recruiting Jinling Hospital, China · Nanjing, Jiangsu · NCT06676527

• Evaluating bicalutamide and sunitinib for advanced kidney cancer

  This study is testing if a combination of two medications, bicalutamide and sunitinib, can help people with advanced kidney cancer who have not responded to previous treatments.

  Recruiting Phase 1/2 State University of New York at Buffalo · Buffalo, New York · NCT06222593

• Analyzing genetic mutations in kidney cells of patients with Von Hippel-Lindau disease

  This study looks at whether kidney cells from people with Von Hippel-Lindau disease have more genetic changes compared to those without the condition.

  Recruiting IRCCS San Raffaele · Milan · NCT06194669

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.